Valuation: Sanofi

Market Cap 90.99B 104B 83.55B 77.94B 148B 9,909B 150B 1,004B 390B 4,868B 391B 382B 16,793B P/E 2026 *
11.4x
P/E 2027 * 10.4x
Enterprise Value 101B 115B 92.43B 86.23B 163B 10,962B 166B 1,111B 432B 5,386B 432B 423B 18,578B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.93x
Free-Float
89%
Yield 2026 *
5.61%
Yield 2027 * 5.95%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 104B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 338B
-0.56%+0.96%+41.67%+39.35% 299B
-0.08%+1.30%+32.15%+44.48% 291B
-1.54%+2.81%-25.35%-39.61% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.89%+4.58%+31.78%+58.22% 410.27B
Weighted average by Cap. +2.18%+5.53%+42.31%+83.31%

Financials

2026 *2027 *
Net sales 47.12B 53.87B 43.26B 40.36B 76.48B 5,131B 77.61B 520B 202B 2,521B 202B 198B 8,695B 50.06B 57.23B 45.96B 42.88B 81.26B 5,451B 82.46B 552B 215B 2,678B 215B 210B 9,238B
Net income 8.4B 9.61B 7.72B 7.2B 13.64B 915B 13.85B 92.73B 36.03B 450B 36.08B 35.3B 1,551B 9.3B 10.64B 8.54B 7.97B 15.1B 1,013B 15.32B 103B 39.88B 498B 39.94B 39.07B 1,717B
Net Debt 9.67B 11.06B 8.88B 8.29B 15.7B 1,053B 15.93B 107B 41.47B 518B 41.53B 40.62B 1,785B 5.86B 6.7B 5.38B 5.02B 9.51B 638B 9.65B 64.64B 25.12B 313B 25.15B 24.6B 1,081B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
75.81EUR
Average target price
96.70EUR
Spread / Average Target
+27.56%

Quarterly revenue - Rate of surprise